MDDA is supported and assisted in its work by a number of organisations who partner with us. Each partner provides a different type of support or assistance.
Biomarin is a world leader in developing and commercialising innovative biopharmaceuticals for rare diseases driven by genetic causes. At BioMarin, they focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations.
Cortex Health is a locally based distributor of highly specialised medical products and medical foods. Their background is in medical research, patient support initiatives and commercialisation within the Australian environment for the Australian community. Their initial product range has been to provide a real alternative to individuals who have Phenylketonuria (PKU).
Menarini Australia is proud of its commitment to supporting the treatment of rare diseases through the provision of highly targeted drugs that assist just a handful of patients. Menarini Australia sits within Menarini Asia-Pacific and in turn the global Menarini Group providing unfettered access to all of the benefits of a large pharmaceutical company with the energy and enthusiasm of a rapidly expanding Australian business.
Nutricia Australia is a division of the French multinational company, Group Danone. Nutricia is recognised as the leader in specialised nutrition and operates in a unique position in the global market as the only company whose entire business is based on nutritional products and support for all age groups.
Orpharma is an Australian pharmaceutical company focused on the supply of orphan, paediatric and emerging therapeutics. In addition, the company will be supplying medical devices for a range of applications. The company was founded to serve unmet medical needs and to provide niche solutions. Orpharma is collaborating with global leaders in biotechnology and pharmaceuticals to deliver therapies to patients in need.
For over 20 years, Vitaflo® has been at the forefront of developing innovative specialised clinical nutrition products for Inborn Errors of Metabolism (IEM). Working in partnership with world key opinion leaders and patients, Vitaflo’s aim is to create products that combine the best of cutting edge research with the lifestyle demands of modern living, ensuring the most acceptable products are available for the patient. Vitaflo Australia Pty Ltd has been distributing products throughout Australia since 2002.